-
公开(公告)号：US20210244815A1
公开(公告)日：2021-08-12
申请号：US17229999
申请日：2021-04-14
Applicant: Genentech, Inc.
Inventor： Chingwei Vivian LEE , Mark S. DENNIS , Germaine FUH
IPC: A61K39/395 , C07K16/28 , C07K16/30 , A61P35/00 , C07K14/725
Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
-
公开(公告)号：US20200002411A1
公开(公告)日：2020-01-02
申请号：US16572822
申请日：2019-09-17
Applicant: Genentech, Inc.
Inventor： Amin FAMILI , Germaine FUH , Patrick KOENIG , Chingwei Vivian LEE , Karthikan RAJAGOPAL
Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
-
公开(公告)号：US20210363231A1
公开(公告)日：2021-11-25
申请号：US17392943
申请日：2021-08-03
Applicant: Genentech, Inc.
Inventor： Amin FAMILI , Germaine FUH , Patrick KOENIG , Chingwei Vivian LEE , Karthikan RAJAGOPAL
Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
-
公开(公告)号：US20200222547A1
公开(公告)日：2020-07-16
申请号：US16575749
申请日：2019-09-19
Applicant: Genentech, Inc. , Ascendis Pharma A/S
Inventor： Sebastian STARK , Thomas KNAPPE , Harald RAU , Nicola BISEK , Burkhardt LAUFER , Samuel WEISBROD , Tobias VOIGT , Germaine FUH , Patrick KOENIG , Chingwei Vivian LEE , Daniela BUMBACA YADAV
IPC: A61K47/61 , A61K47/69 , A61K39/395 , A61K9/00
Abstract: The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.
-
Patent Agency Ranking
公开(公告)号：US20190100581A1
公开(公告)日：2019-04-04
申请号：US16033499
申请日：2018-07-12
Applicant: Genentech, Inc.
Inventor： Patrick KOENIG , Chingwei Vivian LEE , Karthikan RAJAGOPAL , Amin FAMILI , Germaine FUH
IPC: C07K16/22 , C07K16/46 , A61K47/61 , C12N15/10 , C12N15/115 , C07K16/44 , A61K47/34 , A61K47/60 , C07K14/475 , A61K39/395 , A61K39/00
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
公开(公告)号：US20190031750A1
公开(公告)日：2019-01-31
申请号：US16033353
申请日：2018-07-12
Applicant: Genentech, Inc.
Inventor： Patrick KOENIG , Chingwei Vivian LEE , Karthikan RAJAGOPAL , Amin FAMILI , Germaine FUH
IPC: C07K16/22 , A61K47/60 , C07K16/46 , A61K47/61 , C12N15/10 , A61K39/395 , C12N15/115
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
公开(公告)号：US20210115124A1
公开(公告)日：2021-04-22
申请号：US17129251
申请日：2020-12-21
Applicant: Genentech, Inc.
Inventor： Patrick KOENIG , Chingwei Vivian LEE , Karthikan RAJAGOPAL , Amin FAMILI , Germaine FUH
IPC: C07K16/22 , A61K47/60 , A61K47/61 , A61K39/395 , A61K47/34 , C07K14/475 , C07K16/44 , C07K16/46 , C12N15/10 , C12N15/115
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
公开(公告)号：US20180117152A1
公开(公告)日：2018-05-03
申请号：US15836107
申请日：2017-12-08
Applicant: Genentech, Inc.
Inventor： Chingwei Vivian LEE , Mark S. DENNIS , Germaine FUH
IPC: A61K39/395 , C07K16/28 , C07K14/725 , A61P35/00
CPC classification number: A61K39/39558 , A61P35/00 , C07K14/7051 , C07K16/2809 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/92
Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
-
公开(公告)号：US20170096479A1
公开(公告)日：2017-04-06
申请号：US15274612
申请日：2016-09-23
Applicant: Genentech, Inc.
Inventor： Patrick KOENIG , Chingwei Vivian LEE , Karthikan RAJAGOPAL , Amin FAMILI , Germaine FUH
IPC: C07K16/22 , C07K16/46 , C12N15/10 , C12N15/115 , A61K47/34 , C07K16/44 , A61K39/395 , C07K14/475
CPC classification number: C07K16/22 , A61K39/3955 , A61K47/34 , A61K47/60 , A61K47/61 , A61K2039/505 , A61K2039/54 , C07K14/475 , C07K16/44 , C07K16/468 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C12N15/1037 , C12N15/115 , C12N2310/16
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.023 seconds)
